Share This Article

Facebook LinkedIn
Twitter Reddit
Print Email
Pinterest Gmail
Yahoo
Money Morning
×
  • Invest
    • Best Stocks to Buy
    • Stock Forecasts
    • Stocks to Sell Now
    • Stock Market Predictions
    • Technology Stocks
    • Best REITs to Buy Now
    • IPO Stocks
    • Penny Stocks
    • Dividend Stocks
    • Cryptocurrencies
    • Cannabis Investing
    • AI Investing
  • Trade
    • How to Trade Options
    • Best Trades to Make Now
    • Options Trading Strategies
    • Weekly Trade Recommendations
  • Retire
    • Income Investing Guide
    • Retirement Articles
  • More
    • Money Morning LIVE
    • Special Investing Reports
    • Our ELetters
    • Our Premium Services
    • Videos
    • Meet Our Experts
    • Profit Academy
    • Postcards
Login Archives Your Team About Us FAQ
  • Invest
    • Best Stocks to Buy
    • Stock Forecasts
    • Stocks to Sell Now
    • Stock Market Predictions
    • Technology Stocks
    • Best REITs to Buy Now
    • IPO Stocks
    • Penny Stocks
    • Dividend Stocks
    • Cryptocurrencies
    • Cannabis Investing
    • AI Investing
    ×
  • Trade
    • How to Trade Options
    • Best Trades to Make Now
    • Options Trading Strategies
    • Weekly Trade Recommendations
    ×
  • Retire
    • Income Investing Guide
    • Retirement Articles
    ×
  • More
    • Money Morning LIVE
    • Special Investing Reports
    • Our ELetters
    • Our Premium Services
    • Videos
    • Meet Our Experts
    • Profit Academy
    • Postcards
    ×
  • Subscribe
Enter stock ticker or keyword
×
Join 100,000+ Like-Minded Investors Today
Twitter
Tags: Stock Market Today

DJIA Index Notches 5.6% Gain in February

By Garrett Baldwin, Executive Producer, Money Morning • February 27, 2015

Start the conversation

Leave a Reply Click here to cancel reply.

You must be logged in to post a comment.

Garrett BaldwinGarrett Baldwin

The DJIA index dropped 82 points Friday. The cause? Mixed economic data, including a downward revision of fourth-quarter GDP.

Despite today's decline, the DJIA index had its best monthly gain since January 2013. Monthly gains were 5.5% for the S&P 500 - the biggest since October 2011 - and 7.1% for the Nasdaq, the biggest since January 2012.

DJIA indexToday's Scorecard:

Dow: 18,132.38, -82.04, -0.45%       

S&P 500: 2,104.49, -6.25, -0.30%    

Nasdaq: 4,963.53, -24.36, -0.49%

What Moved the DJIA Index Today: Mixed economic data gave investors little enthusiasm to push stocks higher Friday. This morning, the second revision of the Q4 2014 GDP registered at 2.2%, which beat expected growth of 2.1%. Still, the figure slipped from the previous estimate of 2.6%, and the pace is a steep decline from the Q3 2014 final reading of 5%.

Meanwhile, the February reading of the Chicago PMI, an index of business activity in the U.S. Midwest, slipped to its lowest level since July 2009.

[epom key="ddec3ef33420ef7c9964a4695c349764" redirect="" sourceid="" imported="false"]Now, check out the other top market stories - plus get our new profit tip for investors:

  • Earnings Blowout: Shares of Monster Beverage Corp. (Nasdaq: MNST) jumped 13.4% to hit an all-time high today after the company reported a huge earnings beat for the fourth quarter. Quarterly profit surged 65% to $125.3 million. That was well ahead of consensus estimates of $101.5 million. Shares of the Coca-Cola Co. (NYSE: KO), which owns a 16.7% stake in Monster, were up nearly 2% on the day.
  • Oil Posts Monthly Win: Crude oil prices posted their first monthly gains in February since June. Brent crude, priced in London, increased roughly 18.1% for the month, while April 2015 futures for U.S. crude, priced at the NYMEX in New York City, added 3.2% for the month. Domestic crude continues to lag against Brent due to rising inventories and oversupply concerns. The S&P 500 Energy Index was up 0.2% Friday, but energy giants Exxon Mobil Corp. (NYSE: XOM), Chevron Corp. (NYSE: CVX), and ConocoPhillips (NYSE: COP) were down on the day.
  • Net Neutrality Ruling: Investors are still uncertain how to react to yesterday's decision by the Federal Communications Commission (FCC) to pass net neutrality regulations. Under the plan, regulators will prohibit Internet service providers from "discriminating" against a particular online service or website. The only thing certain is that lawsuits are pending, as companies argue that the FCC does not have the unilateral authority to impose the rules. Lawyers are suiting up at Comcast Corp. (Nasdaq: CMCSA), AT&T (NYSE: T), Verizon Communications Inc. (NYSE: VZ), and Time Warner Cable Inc. (NYSE: TWC).
  • Departures: Shares of Bank of America Corp. (NYSE: BAC) slipped more than 1.4% on news that its chief accounting officer and two board directors will be departing from the banking giant in March. Meanwhile, shares of Potbelly Corp. (Nasdaq: PBPB) cratered more than 8.5% after the company announced the resignation of CFO Charlie Talbot. The company received a downgrade from a Piper Jaffray analyst, who called Talbot the glue of the organization.
  • An Apple a Day: Shares of Apple Inc.(Nasdaq: AAPL) fell 1.5% today on news that Ericsson sued the tech giant over 41 alleged cases of patent infringement. The specified patents are central to the functionality of Apple devices, including the popular iPhone. The company has also sent invitations to an event on March 9, telling participants to "Spring Forward." The event, which coincides with the start of Daylight Savings Time, is one month before the company plans to launch the Apple Watch.

Money Morning Tip of the Day: High-margin specialty drugs, and specifically drugs used to treat hepatitis C, offer one of the best profit opportunities right now in the pharmaceutical market.

High-margin specialty drugs are prescription medications that treat complex, chronic, and debilitating diseases. They're very expensive - as much as hundreds of thousands of dollars.

The market for these medications will quadruple over the next five years. Consumer spending on these drugs hit $87.1 billion in 2012. In five years that number will soar to $401.7 billion.

Some of the priciest high-margin specialty drugs include Soliris, developed by Alexion Pharmaceuticals, and Elaprase, by Shire. Soliris treats a rare blood disorder and costs patients roughly $410,000 per year. Elaprase treats Hunter syndrome and costs $375,000 per year.

Those hefty price tags have caused these drug makers' stocks to surge. Since 2010, Alexion has gained 625%, and Shire 275%.

The biggest profit play of all in high-margin specialty drugs comes from makers of hepatitis C treatments. An April 2014 report from Express Scripts found that spending on hepatitis C drugs is expected to increase by more than 200% in both 2015 and 2016.

Newer and more convenient treatments in the coming years will drive sales. And the high price of these hepatitis C drugs will propel the stocks of the pharmaceutical companies that make them to new heights.

Get the best stock pick to play this trend right now, here: "These Pharmaceutical Stocks Let You Tap into a $402 Billion Trend."

 

Here Are 10 “One-Click” Ways to Earn 10% or Better on Your Money Every Quarter

Appreciation is great, but it’s possible to get even more out of the shares you own. A lot more: you can easily beat inflation and collect regular income to spare. There are no complicated trades to put on, no high-level options clearances necessary. In fact, you can do this with a couple of mouse clicks – passive income redefined. Click here for the report…

Claim My Free Report

Garrett BaldwinGarrett Baldwin

About the Author

Browse Garrett's articles |

Garrett Baldwin is a globally recognized research economist, financial writer, consultant, and political risk analyst with decades of trading experience and degrees in economics, cybersecurity, and business from Johns Hopkins, Purdue, Indiana University, and Northwestern.

… Read full bio

Subscribe
Login
Notify of
guest

guest

0 Comments
Inline Feedbacks
View all comments


Latest News

September 15, 2023 • By Shah Gilani

We're Headed for a Second Banking Crisis - Here's What to Do

September 14, 2023 • By Tom Gentile

Tulips Are the Secret to Trading the Next 300% Rally in AI

September 14, 2023 • By Chris Johnson

Tulips Are Telling Me How To Trade the Next 300% rally in AI
Trending Stories
ABOUT MONEY MORNING

Money Morning gives you access to a team of market experts with more than 250 years of combined investing experience – for free. Our experts – who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV – deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors.

QUICK LINKS
About Us COVID-19 Announcements How Money Morning Works FAQs Contact Us Search Article Archive Forgot Username/Password Archives Profit Academy Research Your Team Videos Text Messaging Terms of Use
FREE NEWSLETTERS
Total Wealth Research Power Profit Trades Penny Hawk Midday Momentum
PREMIUM SERVICES
Money Map Press Home Money Map Report Fast Fortune Club Weekly Cash Clock Microcurrency Trader Hyperdrive Portfolio Rocket Wealth Initiative Quantum Data Profits Flashpoint Trader Darknet Alpha Accelerators Brutus Alerts Resource Traders Alliance L.A.U.N.C.H. Investor Rob Roy Trader Long-Term Equity Profits

© 2023 Money Morning All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning.

Address: 1125 N Charles St. | Baltimore, MD, 21201 | USA | Phone: 888.384.8339 | Disclaimer | Sitemap | Privacy Policy | Whitelist Us | Do Not Sell or Share My Personal Information

wpDiscuz